Annotating cancer variants and anti-cancer therapeutics in reactome

Marija Milacic1, Robin Haw, Karen Rothfels

  • 1Informatics and Bio-computing Platform, Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada. robin.haw@oicr.on.ca.

Cancers
|November 12, 2013
PubMed

Insights

Reactome now annotates cancer pathways by extending its data model to include disease attributes and protein modifications. This enables visualization of cancer variants and comparison with normal pathways for therapeutic insights.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Bioinformatics

Background:

  • Reactome models biological pathways as chemical reactions mirroring cellular interactions.
  • Existing Reactome data structures require extension to incorporate disease-specific information, particularly for cancer.

Purpose of the Study:

  • To extend the Reactome data model for annotating cancer and other disease processes.
  • To enhance pathway visualization and analysis tools for disease variants.

Main Methods:

  • Extended the protein modification class to include amino acid sequence changes and fusion proteins relevant to disease.
  • Added a disease attribute to reaction, pathway, and physical entity classes, utilizing disease ontology terms.
  • Adapted the Pathway Browser for graphical representation and comparison of disease variants with wild-type pathways.

Main Results:

  • The extended Reactome model now accommodates annotation of disease-related protein alterations.
  • Disease attributes integrated into Reactome allow for specific tracking of disease pathways.
  • The Pathway Browser visualizes cancer pathway variants, their connections to other pathways, and therapeutic interventions.

Conclusions:

  • Reactome's data model extensions facilitate comprehensive annotation of cancer pathways.
  • These enhancements enable interoperability with existing pathway and network analysis tools.
  • The updated Reactome system provides insights into altered biological behavior in diseases like cancer, aiding therapeutic development.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.1K